NKGN (NKGen Biotech) Shares Outstanding (EOP): 51.31 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NKGen Biotech Shares Outstanding (EOP)?

NKGen Biotech NKGN Shares Outstanding (EOP) is 51.31 Mil as of Mar. 2025.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. NKGen Biotech's shares outstanding for the quarter that ended in Mar. 2025 was 51.31 Mil.

NKGen Biotech's quarterly shares outstanding increased from Dec. 2024 (44.24 Mil) to Mar. 2025 (51.31 Mil). It means NKGen Biotech issued new shares from Dec. 2024 to Mar. 2025 .

NKGen Biotech's annual shares outstanding increased from Dec. 2023 (21.89 Mil) to Dec. 2024 (44.24 Mil). It means NKGen Biotech issued new shares from Dec. 2023 to Dec. 2024 .


NKGen Biotech  (OTCPK:NKGN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


NKGen Biotech Shares Outstanding (EOP) Related Terms


NKGen Biotech Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for NKGen Biotech's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech Shares Outstanding (EOP) Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
21.89 21.89 21.89 44.24

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.39 25.77 35.72 44.24 51.31

NKGN vs CALC, CLGN, MBRX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, NKGen Biotech's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Shares Outstanding (EOP) falls into.



NKGen Biotech Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 51.31 Mil mean?
NKGen Biotech (NKGN) has a Shares Outstanding (EOP) of 51.31 Mil as of Mar. 2025. The total shares a company has outstanding, at period-end. View historical data on NKGen Biotech and its competitors.
Is NKGen Biotech's Shares Outstanding (EOP) too high?
NKGen Biotech's current Shares Outstanding (EOP) is 51.31 Mil.
How does NKGen Biotech's Shares Outstanding (EOP) compare to CALC and CLGN?
NKGen Biotech's Shares Outstanding (EOP) of 51.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on NKGen Biotech and its competitors. NKGen Biotech's current Shares Outstanding (EOP) is 51.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NKGen Biotech stock overvalued right now?
NKGen Biotech (NKGN) has a current Shares Outstanding (EOP) of 51.31 Mil. The current Shares Outstanding (EOP) is 51.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For NKGen Biotech (NKGN), the current Shares Outstanding (EOP) is 51.31 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NKGen Biotech Business Description

Address 3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.